<DOC>
	<DOCNO>NCT02082626</DOCNO>
	<brief_summary>This study child cancer curative treatment option . The investigator give eribulin , new chemotherapy agent , first time child . This study design determine safe dose investigator give child large study . The investigator monitor child study safety treatment level eribulin blood treatment . The investigator also study effect agent cancer .</brief_summary>
	<brief_title>Study Eribulin Children With Cancer Determine Safety</brief_title>
	<detailed_description>This phase I study eribulin , novel tubulin inhibitor child relapse refractory solid tumor include lymphoma . Dose escalation perform classic 3+3 design start 75 % adult maximum tolerate dose ( MTD ) . Pharmacokinetics do patient . Primary endpoint pediatric MTD .</detailed_description>
	<criteria>Age : â‰¤ 21 year age time study enrollment Diagnosis : refractory recurrent solid tumor , include lymphoma , except CNS tumor know CNS metastases Disease Status : measurable evaluable disease Adequate organ function define protocol Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Cancer</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Eribulin</keyword>
</DOC>